Largest $ Movers of Note - StreetInsider.com - 03/23/2007

March 23, 2007 1:35 PM EDT

UPWARD MOVERS:
Bel Fuse Inc. (NASDAQ: BELFA) +$9.30; Technitrol, Inc., (NYSE: TNL) has sent a letter to the Board of Directors of Bel Fuse Inc. (NASDAQ: BELFA) (Nasdaq: BELFB) offering to acquire the company for $40.30 per share, or $480 million, in cash. The offer price represents premiums of 38% and 21% to the closing prices on Thursday, March 22, 2007 of Bel Fuse's Class A and Class B shares, respectively.

Kronos Incorporated (Nasdaq: KRON) +$6.33; Kronos has signed a definitive agreement to be acquired by the private equity firm Hellman & Friedman Capital Partners VI, L.P. and its related funds in a transaction valued at approximately $1.8 billion. Under the terms of the agreement, Kronos shareholders will receive $55.00 in cash for each share of Kronos common stock, representing a 34.4% premium over Kronos' closing share price from 20 trading days ago.

Daimlerchrysler AG (NYSE: DCX) +$4.82; Stock moving up after reports Magna Int'l (NYSE: MGA) is teaming up with private equity firms to offer a bid to acquire Daimlerchrysler AG's (NYSE: DCX) Chrysler unit. The report says the bid could be $4.6-4.7 billion.

Paxar Corporation (NYSE: PXR) +$4.45; Avery Dennison Corporation (NYSE: AVY) and Paxar announced that their boards of directors have unanimously approved a definitive agreement for Avery Dennison to acquire all outstanding shares of Paxar for $30.50 per share in a cash transaction valued at approximately $1.34 billion.

MEMC Electronic Materials Inc. (NYSE: WFR) +$2.84; Stock continues higher with no specific news releases.


DOWNWARD MOVERS:
Genentech Inc. (Nasdaq: DNA) -$3.21; Says Avastin lung cancer study stopped for safety, says study was in small cell lung cancer, DNA notifying doctors of trachea issue.

CECO Environmental Corp. (Nasdaq: CECE) -$2.98; Reports Q4 EPS of $0.09 vs. consensus of $0.20. Revenues were $41.5 million vs. consensus of $37.25 million.

Jabil Circuit (NYSE: JBL) -$2.52; Reports Q2 revenues, delays EPS report. Stock receives multiple downgrades this morning.

Amgen (NASDAQ: AMGN) -$2.18; Company has discontinued Vectibix treatment in the PACCE trial evaluating the addition of Vectibix to standard chemotherapy and Avastin for the treatment of first-line metastatic colorectal cancer. The PACCE trial investigated a treatment regimen that used dual biologics combined with oxaliplatin- or irinotecan-based chemotherapy. This regimen is not currently used in clinical practice.

Priceline.com Inc. (Nasdaq: PCLN) -$2.12; Stock moving lower with no specific news releases. Today's move could be attributed to profit taking.

Related Categories

Special Reports

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?